<DOC>
	<DOCNO>NCT01270828</DOCNO>
	<brief_summary>The purpose study explore safety efficacy new day pregabalin formulation versus placebo patient post herpetic neuralgia ( Shingles )</brief_summary>
	<brief_title>Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients must pain present 3 month heal herpes zoster skin rash . At screen ( V1 ) enrollment ( V2 ) , patient must score great equal 4 Pain Numeric Rating Scale ( 1 week recall period ) . At enrollment ( V2 ) , least 4 pain diary must complete satisfactorily within last 7 day average pain score must great equal 4 . Male female race , least 18 year age , use appropriate method contraception Creatinine clearance &lt; 30 mL/min ( estimate serum creatinine ) . Skin condition affect dermatome could alter sensation Pregabalin use last 30 day . Subjects take pregabalin last 30 day wash pregabalin least 30 day prior screen visit . Patients respond pregabalin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Control Release Pregabalin Post Herpetic Neuralgia</keyword>
</DOC>